Breaking News, Collaborations & Alliances

PharmaKure Partners with Sheffield Hallam University to Better Understand Alzheimer’s

Collaboration will focus on epigenetic markers for calculating risk scores for Alzheimer’s diseases.

Author Image

By: Charlie Sternberg

Associate Editor

PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, has announced a new epigenetics collaboration with Sheffield Hallam University, which will focus on ‘gene-based environmental biomarkers’, known as epigenetic markers, for calculating risk scores for Alzheimer’s diseases.   Together with ALZmetrix, PharmaKure’s blood-based biomarker, this will increase the power of current Alzheimer’s diagnostics...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters